Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More New York-based Catalyst, a company mobilizing customer data for ...

After the acquisition of Podium Data by Qlik last July, we knew a couple of things: consolidation in the analytics market was continuing, and interest in data governance/data management was increasing ...

Qlik has released Qlik Data Catalyst 4.0, the latest version of the data management product it rebranded from Podium Data early last year. Qlik Data Catalyst 4.0 supports data sources beyond Hadoop, ...

The smart utilization of data has transformed nearly every sector of American life, from the way we do business to the entertainment we consume. But it’s also a major driver in health care. The right ...

PHILADELPHIA--(BUSINESS WIRE)--Qlik continues to execute on its mission to provide enterprise customers with end-to-end data management and analytics solutions with the release of Qlik Data Catalyst™ ...

SAN JOSE, Calif.--(BUSINESS WIRE)--Cohesity, a leader in data security and management, today announced Cohesity Catalyst, the leading data security and management summit, will be held as a three-day ...

Harmony Biosciences remains a Buy due to strong Wakix growth, profitability, and undervalued metrics despite recent setbacks. Upcoming catalysts—especially ZYN002 Phase 3 data in Fragile X—could drive ...

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the data ...

Managing your customers has changed a lot in the past decade. Out are the steak dinners and ballgame tickets to get a sense of a contract’s chance at renewal, and in are churn analysis and a whole ...

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced positive efficacy and safety data from its Phase 2b trial of DalcA, a ...

Enrollment in the DalcA trial is complete; results demonstrate DalcA provides Factor IX (FIX) activity exceeding the efficacy endpoint with no anti-drug antibodies Company to host investor call and ...